Jyong Biotech’s Botreso® Completes Four Phase III Trials; PCP Shows Cancer Prevention Trends
Jyong Biotech’s Botreso® completed four Phase III trials in the US and Taiwan, and its PCP drug finished a two-year Phase II study with 702 subjects across 20 hospitals, showing no drug-related adverse events. Clinical data highlight metabolic improvements—reduced triglycerides, lower LDL, higher HDL—and PCP trends toward prostate cancer prevention.
1. Clinical Trial Results
Botreso® has completed four Phase III trials in the United States and Taiwan assessing efficacy and safety over a one-year treatment period. PCP conducted a two-year Phase II trial involving 702 subjects across 20 hospitals, with data indicating trends toward reduced overall and high-grade prostate cancer incidence.
2. Safety and Metabolic Benefits
Neither Botreso® nor PCP triggered drug-related serious adverse events during their respective one-year and two-year dosing periods. Clinical analyses revealed significant metabolic improvements: reduced triglycerides (P=0.05), lowered total cholesterol and LDL (P<0.05), increased HDL (P<0.05), and stable blood glucose, without negative impacts on blood pressure, liver, or kidney function.
3. Technological Platform and Competitive Barriers
Jyong Biotech has established a comprehensive technology platform for botanical drugs, encompassing purification processes, reference standard development, analytical method validation, and verification protocols. This integrated capability poses significant replication challenges, reduces counterfeit risks, and supports extended market exclusivity.
4. Market Strategy and Licensing Potential
With global patents and botanical new drug status, Jyong Biotech aims for premium pricing and high-end market penetration. The global BPH treatment market is projected at $9.8 billion by 2026 and could exceed $20 billion under on-patent pricing. Letters of intent with international partners signal licensing and expansion prospects.